Responsable(s)
Directeur - Le responsable ne souhaite pas publier ses coordonnées.
|
|
Etablissements. |
|
INSERM - Institut national de la sante et de la recherche medicale (U 1177)
(établissement tutelle à
partir de 2006)
|
|
INST PASTEUR LILLE - Institut Pasteur de Lille ( null)
(établissement tutelle à
partir de 2006)
|
|
LILLE - Université de Lille (EPE) (UMR_S 761)
(établissement tutelle à
partir de 2018)
Etablissement référent
|
Adresse
Faculté des Sciences PharmaceUtiques et Biologiques rue du Professeur Laguesse 83
59006 LILLE
|
Contact
courriel : benoit.deprez@univ-lille2.fr
|
| Site web :
https://www.deprezlab.fr/
|
| Taille en ETP (sans compter les stagiaires):
entre 10 et 50.
|
Descriptif :
The mission of the lab is to pioneer new pharmacological modes-of-action with the aim to provide drug prototypes in areas of unmet medical need.
Working exclusively on novel targets or novel strategies to tackle challenging modes of action, we position ourselves upstream of traditional players (i.e pharmaceutical or biotech companies), assuming risk at early stages of the drug discovery value chain. This positioning aims at combining new knowledge on biology and pharmacology with therapeutic innovation.
To fulfil its mission, the team designs, synthesizes and evaluates novel compounds (both qualitatively and quantitatively) in living systems (cells, organism, human). Specifically, we design and study compounds that selectively modulate molecular targets to understand (chemical biology) and treat (drug discovery) infectious and metabolic diseases.
To reach these goals, our team collaborates actively and shares resources with biologists and medical doctors from various French INSERM and CNRS laboratories (CIIL, Labex Egid, Lille, Insititut Necker, Paris) and with specialists in the formulation area (Paris-Orsay, Lille) and molecular modelling (MTI, U973 B. Villoutreix, Paris). In parallel, we have sustained relationships with several university labs abroad: U.Chicago, Ho-Chi-Min Ville, Durham, Leuven, Athens and Brussels. Our unit is the only academic lab in France combining extensive resources in synthetic chemistry, bioanalytics and pharmacological screening and pharmacokinetics, enabling continuing commitment from target identification to drug prototype.
|
| Année de création :
2006
|
| Mission de la structure :
Recherche
|
| Mode de gestion de la structure :
Non renseigné.
|
| SIRET de la structure :
Non renseigné.
|
Classement scientifique ERC
- LS1 : Molecules of Life: Biological Mechanisms, Structures and Functions : Molecular biology, biochemistry, structural biology, molecular biophysics, synthetic and chemical biology, drug design, innovative methods and modelling
- LS7 : Prevention, Diagnosis and Treatment of Human Diseases : Medical technologies and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions, pharmacology, preventative medicine, epidemiology and public health, digital medicine
- LS6 : Immunity, Infection and Immunotherapy : The immune system, related disorders and their mechanisms, biology of infectious agents and infection, biological basis of prevention and treatment of infectious diseases, innovative immunological tools and approaches, including therapies
- PE7 : Systems and communication engineering : Electrical, electronic, communication, optical and systems engineering
|
Domaine scientifique
- 4 : Chimie 2015 0
- 5 : Biologie, médecine et santé 2006 0
|
Ecole(s) doctorale(s) de rattachement
Non renseigné
|
Rattachée au(x) programme(s) LOLF suivant(s):
- prg172-05 : Recherches scientifiques et technologiques en sciences de la vie, biotechnologies et santé
|
Rattachée au(x) thème(s) de recherche suivant(s):
infectious diseases (target pathways encoded by bacteria),;
metabolic and immune diseases (human-encoded target pathways);
quantitative pharmacology: High Throughput Screening, High Resolution Screening (phenotypic, HRMS-guided), pharmacokinetics, new probes and reporters to be used in confocal microscopy.;
medicinal chemistry and structure-based design:;
fragment-based drug discovery, molecular modelling, organic chemistry, in situ target-guided synthesis, chemical library development;
|
Liens avec d'autres structures :
Regroupe :
-
Groupements d'Intérêt scientifique 201823610P - ChemBioFrance
(lien non exclusif)
Participe à :
-
Structures Fédératives de Recherche 201220468A - Institut Européen de Génomique du Diabète
(lien non exclusif)
|
Site ESR :
Aucun.
|
Fiche mise à jour par Laurence Neydt le 21/03/2022 à 13:44
|
